NasdaqGS:AKCA

Stock Analysis Report

Executive Summary

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally.


Snowflake Analysis

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Akcea Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AKCA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.2%

AKCA

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

-33.5%

AKCA

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: AKCA underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: AKCA underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

AKCAIndustryMarket
7 Day1.2%0.7%-1.1%
30 Day0.4%5.6%1.4%
90 Day-4.4%6.2%6.9%
1 Year-33.5%-33.5%14.9%14.0%20.3%17.9%
3 Yearn/a24.4%21.1%47.8%38.3%
5 Yearn/a3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Akcea Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Akcea Therapeutics undervalued compared to its fair value and its price relative to the market?

5.24x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AKCA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AKCA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AKCA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: AKCA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AKCA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AKCA is overvalued based on its PB Ratio (5.2x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Akcea Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

35.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AKCA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKCA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKCA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AKCA's revenue (26.8% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: AKCA's revenue (26.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AKCA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Akcea Therapeutics performed over the past 5 years?

-27.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AKCA is currently unprofitable.

Growing Profit Margin: AKCA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AKCA is unprofitable, and losses have increased over the past 5 years at a rate of -27.2% per year.

Accelerating Growth: Unable to compare AKCA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKCA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (66.2%).


Return on Equity

High ROE: AKCA has a negative Return on Equity (-34.47%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Akcea Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AKCA's short term assets ($278.4M) exceed its short term liabilities ($43.1M).

Long Term Liabilities: AKCA's short term assets ($278.4M) exceed its long term liabilities ($14.6M).


Debt to Equity History and Analysis

Debt Level: AKCA is debt free.

Reducing Debt: AKCA had no debt 5 years ago.


Balance Sheet

Inventory Level: AKCA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AKCA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKCA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AKCA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -29.2% each year


Next Steps

Dividend

What is Akcea Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AKCA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AKCA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AKCA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKCA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKCA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Damien McDevitt (52yo)

0.4yrs

Tenure

0

Dr. Damien McDevitt, Ph.D., serves as Interim Chief Executive Officer of Akcea Therapeutics, Inc. since September 23, 2019 and its Director since October 04, 2018. He served as Chief Business Officer of Io ...


Leadership Team

NamePositionTenureCompensationOwnership
Damien McDevitt
Interim CEO & Director0.4yrsno data0.21% $3.6m
Paula Soteropoulos
0.4yrsUS$5.21m0.72% $12.3m
Jeffrey Goldberg
0.4yrsUS$7.65m0.17% $2.8m
Michael MacLean
Chief Financial Officer2.5yrsUS$4.52m0.021% $363.6k
Alex Howarth
Chief Operating Officer0.2yrsno data0.053% $909.0k
Kathleen Gallagher
Vice President of Corporate Communications & Investor Relations0yrsno datano data
Maura Bullock
Vice President of Human Resources1.6yrsno datano data
Louis St. O'Dea
Chief Medical Officer4.1yrsUS$1.66m0.021% $363.6k
Kyle Jenne
Chief Commercial Officer2.8yrsno data0.039% $667.5k
Bernard Parker
VP & Global Franchise Head - TTR0yrsno datano data

1.0yrs

Average Tenure

52yo

Average Age

Experienced Management: AKCA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Damien McDevitt
Interim CEO & Director0.4yrsno data0.21% $3.6m
Christopher Gabrieli
Independent Director3.8yrsUS$563.58k0.049% $840.4k
B. Parshall
Chairman of the Board0.2yrsUS$1.51m0.021% $360.9k
Sandford Smith
Independent Director2.9yrsUS$592.58k0.035% $600.2k
Elaine Hochberg
Independent Director2.9yrsUS$533.58k0.035% $600.2k
Edward Fitzgerald
Independent Director2.8yrsUS$590.58k0.035% $600.2k
Joseph Witztum
Member of Cardio Metabolic Advisory Board0yrsno datano data
Johannes Jacob Kastelein
Member of Cardio Metabolic Advisory Board0yrsno datano data
Sotirios Tsimikas
Member of Cardio Metabolic Advisory Board0yrsno datano data
Rosanne Crooke
Member of Cardio Metabolic Advisory Board0yrsno datano data

2.8yrs

Average Tenure

64yo

Average Age

Experienced Board: AKCA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.


Top Shareholders

Company Information

Akcea Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Akcea Therapeutics, Inc.
  • Ticker: AKCA
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.707b
  • Shares outstanding: 93.90m
  • Website: https://www.akceatx.com

Number of Employees


Location

  • Akcea Therapeutics, Inc.
  • 22 Boston Wharf Road
  • 9th Floor
  • Boston
  • Massachusetts
  • 2210
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKCANasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 2017
1KADB (Deutsche Boerse AG)YesCommon StockDEEURJul 2017

Biography

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 02:46
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.